Benitec Biopharma Inc. (BNTC) announced continued durable improvements in swallowing following administration of the low-dose of BB-301 in the study's first two subjects treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study in Oculopharyngeal Muscular Dystrophy or OPMD.
According to the company, two Subjects received the lowest dose of gene therapy BB-301 (1.2e13 vg/subject), with no significant adverse events reported. At baseline, Subject 1 exhibited more severe dysphagic symptoms compared to Subject 2, as assessed by pre-dose SSQ and TPR results. However, both subjects experienced significant clinical benefits, as indicated by their post-dose SSQ scores and TPR results.
The SSQ Total Scores and Sub-Scores demonstrated a strong correlation with the VFSS TPR results. Subject 1 showed clinically meaningful improvements in the post-dose SSQ Total Score and Sub-Scores by Day 270, which were driven by corresponding reductions in VFSS TPR values. Meanwhile, Subject 2 achieved clinically meaningful improvements in the post-dose SSQ Total Score and Sub-Scores by Day 180, reaching a score indicative of a normal swallowing profile, primarily due to a reduction in the frequency of pathologic low-volume sequential swallows.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.